Assembly Biosciences (ASMB) Non-Current Deffered Revenue (2017 - 2025)

Assembly Biosciences' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $1.7 million for Q3 2025.

• In Q3 2025, Non-Current Deffered Revenue fell 94.72% year-over-year to $1.7 million; the TTM figure through Sep 2025 stood at $1.7 million (down 94.72% YoY), while the FY2024 annual figure was $35.4 million, down 36.12% from the prior year.
• Non-Current Deffered Revenue for Q3 2025 stood at $1.7 million, down from $13.0 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $55.4 million in Q4 2023, with the low at $1.7 million in Q3 2025.
• The 5-year median for Non-Current Deffered Revenue is $2.7 million (2021), against an average of $13.9 million.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deffered Revenue soared 1926.31% in 2023, then tumbled 94.72% in 2025.
• Assembly Biosciences' Non-Current Deffered Revenue stood at $2.7 million in 2021, then changed by 0.0% to $2.7 million in 2022, then jumped by 1926.31% to $55.4 million in 2023, then sank by 36.12% to $35.4 million in 2024, then tumbled by 95.15% to $1.7 million in 2025.
• Business Quant data shows ASMB's Non-Current Deffered Revenue at $1.7 million in Q3 2025, $13.0 million in Q2 2025, and $22.8 million in Q1 2025.